News

  • SBIR Reauthorization Status as of November

    • November 12, 2025
      • News
    • SBIR Program

    SBIR and STTR programs lapsed on Sept. 30, 2025, halting new awards. Agencies await reauthorization, likely via the FY2026 NDAA. Here’s where things stand and what’s next for small tech firms.

  • SBIR’s 22:1 Return—and Fight for Survival

    • September 30, 2025
      • News
    • SBIR Program

    A small federal program with a $22-to-$1 return is at risk. Discover how SBIR quietly fueled America’s innovation engine—and why its future now hangs in the balance.

  • The Global Rise of the SBIR Innovation Model

    • September 29, 2025
      • News
    • SBIR Program

    SBIR began as a U.S. experiment. Now it’s a global model for startup innovation, adopted by over 17 countries. Discover how the program reshaped R&D worldwide.

  • From NASA Algae to Baby Formula: Martek’s Rise

    • September 26, 2025
      • News
    • SBIR Program

    A NASA algae experiment led to a biotech breakthrough now nourishing 50 million babies. See how SBIR funding helped Martek reshape infant nutrition worldwide.

  • From Jet Tanks to Crowds: Lifeline’s SBIR Path

    • September 25, 2025
      • News
    • SBIR Program

    A lifesaving sensor system born in Air Force hangars is now protecting firefighters, crowds, and disaster zones—thanks to SBIR funding and public safety innovation.

  • How SBIR Helped Defeat ‘Forever Chemicals’

    • September 24, 2025
      • News
    • SBIR Program

    A young startup backed by SBIR grants has built a machine that destroys toxic PFAS chemicals—once thought indestructible. It’s a game-changer for clean water.

  • How SBIR Grants Attract Venture Capital

    • September 22, 2025
      • News
    • SBIR Program

    New research confirms it: SBIR grants don’t replace venture capital—they attract it. Startups with SBIR funding raise more VC money and reach bigger exits.

  • Genzyme: $62K Grant to $20B Biotech Giant

    • September 19, 2025
      • News
    • SBIR Program

    Genzyme’s $62K SBIR grant became a $20.1B success story. Learn how this biotech startup turned rare disease research into one of the biggest pharma deals ever.

  • How SBIR Fuels Big Pharma Breakthroughs

    • September 18, 2025
      • News
    • SBIR Program

    From cancer cures to hepatitis treatments, SBIR-funded startups have quietly delivered life-saving drugs. Discover how small businesses are reshaping pharma.

Next